Hybrigenics has published data from a Phase II study in chronic myeloid leukaemia (CML). After one year of treatment, 40% of patients showed improvements beyond a major molecular response (MMR) and 20% achieved a deep molecular response (DMR), consistent with a functional cure. The ongoing Phase II trial in acute myeloid leukaemia (AML) will complete enrolment before end 2018, with data readout in 2019. Hybrigenics has completed its refocusing on R&D with the sale of the genomics division
24 May 2018
Hybrigenics - Leukaemia pipeline advances with new data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hybrigenics - Leukaemia pipeline advances with new data
Hybrigenics SA Class A (ALHYG:PAR) | 0 0 0.0% | Mkt Cap: 25.2m
- Published:
24 May 2018 -
Author:
Juan Pedro Serrate -
Pages:
5
Hybrigenics has published data from a Phase II study in chronic myeloid leukaemia (CML). After one year of treatment, 40% of patients showed improvements beyond a major molecular response (MMR) and 20% achieved a deep molecular response (DMR), consistent with a functional cure. The ongoing Phase II trial in acute myeloid leukaemia (AML) will complete enrolment before end 2018, with data readout in 2019. Hybrigenics has completed its refocusing on R&D with the sale of the genomics division